Literature DB >> 11568035

Sustained angina relief 5 years after transmyocardial laser revascularization with a CO(2) laser.

K A Horvath1, S F Aranki, L H Cohn, R J March, O H Frazier, K A Kadipasaoglu, S W Boyce, B W Lytle, K P Landolfo, J E Lowe, B Hattler, B P Griffith, A M Lansing.   

Abstract

BACKGROUND: Although transmyocardial laser revascularization (TMR) has provided symptomatic relief of angina over the short term, the long-term efficacy of the procedure is unknown. Angina symptoms as assessed independently by angina class and the Seattle Angina Questionnaire (SAQ) were prospectively collected up to 7 years after TMR.
METHODS: Seventy-eight patients with severe angina not amenable to conventional revascularization were treated with a CO(2) laser. Their mean age was 61+/-10 years at the time of treatment. Preoperatively, 66% had unstable angina, 73% had had >/=1 myocardial infarction, 93% had undergone >/=1 CABG, 42% had >/=1 PTCA, 76% were in angina class IV, and 24% were in angina class III. Their average pre-TMR angina class was 3.7+/-0.4.
RESULTS: After an average of 5 years (and up to 7 years) of follow-up, the average angina class was significantly improved to 1.6+/-1 (P=0.0001). This was unchanged from the 1.5+/-1 average angina class at 1 year postoperatively (P=NS). There was a marked redistribution according to angina class, with 81% of the patients in class II or better, and 17% of the patients had no angina 5 years after TMR. A decrease of >/=2 angina classes was considered significant, and by this criterion, 68% of the patients had successful long-term angina relief. The angina class results were further confirmed with the SAQ; 5-year SAQ scores revealed an average improvement of 170% over the baseline results.
CONCLUSIONS: The long-term efficacy of TMR persists for >/=5 years. TMR with CO(2) laser as sole therapy for severe disabling angina provides significant long-term angina relief.

Entities:  

Mesh:

Year:  2001        PMID: 11568035     DOI: 10.1161/hc37t1.094774

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  10 in total

Review 1.  Transmyocardial laser revascularization versus medical therapy for refractory angina.

Authors:  Eduardo Briones; Juan Ramon Lacalle; Ignacio Marin-Leon; José-Ramón Rueda
Journal:  Cochrane Database Syst Rev       Date:  2015-02-27

Review 2.  Transmyocardial laser revascularization.

Authors:  Keith A Horvath
Journal:  J Card Surg       Date:  2008 May-Jun       Impact factor: 1.620

3.  Transmyocardial laser revascularization as an adjunct to coronary artery bypass grafting: a randomized, multicenter study with 4-year follow-up.

Authors:  O H Frazier; Egemen Tuzun; Harald Eichstadt; Steven W Boyce; Allan M Lansing; Robert J March; Michele Sartori; Kamuran A Kadipasaoglu
Journal:  Tex Heart Inst J       Date:  2004

4.  Selection of optimal therapy for chronic stable angina.

Authors:  Udho Thadani
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-02

5.  Does laser type impact myocardial function following transmyocardial laser revascularization?

Authors:  Soren K Estvold; Frederico Mordini; Yifu Zhou; Zu X Yu; Vandana Sachdev; Andrew Arai; Keith A Horvath
Journal:  Lasers Surg Med       Date:  2010-12       Impact factor: 4.025

6.  Transmyocardial revascularization (TMR): current status and future directions.

Authors:  Keith B Allen; Amy Mahoney; Sanjeev Aggarwal; John Russell Davis; Eric Thompson; Alex F Pak; Jessica Heimes; A Michael Borkon
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2018-10-08

7.  Health-related quality of life in patients with coronary artery disease treated for angina: validity and reliability of German translations of two specific questionnaires.

Authors:  S Höfer; W Benzer; G Schüssler; N von Steinbüchel; N B Oldridge
Journal:  Qual Life Res       Date:  2003-03       Impact factor: 4.147

8.  Transmyocardial Laser Revascularization.

Authors:  Keith A. Horvath
Journal:  Curr Treat Options Cardiovasc Med       Date:  2004-02

9.  Long-term follow-up assessment of a phase 1 trial of angiogenic gene therapy using direct intramyocardial administration of an adenoviral vector expressing the VEGF121 cDNA for the treatment of diffuse coronary artery disease.

Authors:  Todd K Rosengart; Muath M Bishawi; Michael S Halbreiner; Mathew Fakhoury; Eileen Finnin; Charleen Hollmann; Annie Laurie Shroyer; Ronald G Crystal
Journal:  Hum Gene Ther       Date:  2012-12-20       Impact factor: 5.695

Review 10.  Transmyocardial revascularization devices: technology update.

Authors:  Bogdan A Kindzelski; Yifu Zhou; Keith A Horvath
Journal:  Med Devices (Auckl)       Date:  2014-12-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.